follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

MYOS Corp. appoints new chief medical officer

By

Back to Top Comments Print

Latest News

advertisement

Cedar Knolls-based MYOS Corporation, an emerging biotherapeutics and bionutrition company, announced Thursday the appointment of Robert C. Ashton as chief medical officer.

According to the announcement, Ashton will lead the company's clinical research efforts and serve on the management committee and the joint research and development committee. He will also be responsible for the expansion of MYO-T12, known as Fortetropin, and sold under the brand name MYO-X. MYOS plans to conduct further clinical studies of the drug in the treatment of age-associated muscle loss and sarcopenia associated with chronic illnesses such as cancer.

Ashton has over 25 years of experience both as a surgeon and in building healthcare businesses. He is a board-certified thoracic and general surgeon and has broad clinical experience. He previously was the chief and vice-chairman of the Cancer Center at Hackensack University Medical Center, the announcement said.

ALSO ON NJBIZ:

Harrison Mayor McDonough remembered as a champion of redevelopment

Two N.J. companies earn spot on list of top 50 companies for women

Latest ACA enrollment numbers lower than expected

Emily Bader

Emily Bader

Emily Bader is the copy and web editor at NJBIZ. She is a Brielle, N.J. native and a Rutgers University alum. You can contact her at emilyb@njbiz.com or @emilybader on Twitter.

advertisement

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top